Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
This marks the second indication for which gumokimab has gained NDA review acceptance
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Subscribe To Our Newsletter & Stay Updated